QT Vascular

Is it making any real profits yet? If not then its a waste of time, counter for speculators.

sent from my Galaxy Tab S

(09-06-2015, 07:19 PM)BlueKelah Wrote: Is it making any real profits yet? If not then its a waste of time, counter for speculators.

sent from my Galaxy Tab S

very true, but if you don't number crunching, the prospects is very good though is hard to quantify. QTV can be possibly a takeover target judging on the progress of Chocolate Touch and the track record of Dr. Eitan Konstantino.

trading halt...

let me guess,

i) private placement
ii) right issue

M&A at this time is not likely IMO.

(03-07-2015, 04:40 PM)valuebuddies Wrote: trading halt...

let me guess,

i) private placement
ii) right issue

M&A at this time is not likely IMO.

The company is in trouble. Run out of fund and now lost USD 20 millions suit. This will affect the just announced 12 million fund raising or not?

Quote:http://www.nasdaq.com/press-release/fede...0702-00240

Federal Court in California Awards AngioScore $20 Million Plus Disgorgement in Breach of Fiduciary Duty Case

Read more: http://www.nasdaq.com/press-release/fede...z3eq4l0tu9

COLORADO SPRINGS, Colo., July 2, 2015 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that the U.S. District Court for the Northern District of California has ruled in favor of its wholly-owned subsidiary, AngioScore Inc., in a lawsuit filed by AngioScore seeking damages for breach of fiduciary duty against Eitan Konstantino, a former board member of AngioScore and founder of TriReme Medical, LLC, Quattro Vascular Pte Ltd. and QT Vascular Ltd. (SGX:5I0). The Court found that Konstantino breached his fiduciary duties to AngioScore, that TriReme and Quattro aided and abetted that breach, and that QT Vascular is liable for the acts of TriReme and Quattro. The Court awarded AngioScore $20.034 million against all defendants plus disgorgement from Konstantino of all benefits he accrued from his breach of fiduciary duties, including amounts he received for assigning his intellectual property rights to the Chocolate balloon, a royalty on past and future sales of the Chocolate balloon, and all of his shares and options in QT Vascular. Under the indemnification agreement between AngioScore and Konstantino, AngioScore will seek to recover attorney fees and costs previously advanced to Konstantino.

In its ruling, the Court found that Konstantino, a former co-founder, officer and member of the board of directors of AngioScore, breached his fiduciary duties to AngioScore by developing the Chocolate balloon catheter while serving on the AngioScore board and failing to present that corporate opportunity to AngioScore. Konstantino subsequently launched the product through TriReme, Quattro and QT Vascular.

Spectranetics acquired AngioScore in June 2014.

About Spectranetics

SPNC develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are sold in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.

The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt® scoring balloon used in both peripheral and coronary procedures and Stellarex™ drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.

The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.

For more information, visit www.spectranetics.com.

CONTACT: COMPANY CONTACT
The Spectranetics CorporationGuy Childs, Chief Financial Officer
(719) 633-8333

INVESTOR CONTACT
Westwicke PartnersLynn Pieper
(415) 202-5678
lynn.pieper@westwicke.com
Source: The Spectranetics Corporation

Read more: http://www.nasdaq.com/press-release/fede...z3eq4OyTVd

Not vested.

as I said before, not making money and making losses, speculative waste of time.

-ve 30% today after halt, getting more interesting.

http://www.theedgemarkets.com/sg/article...on-damages

NEW YORK (July 8): QT Vascular announced that the US federal district court has awarded damages of US$20.03 million ($27.2 million) to AngioScore, Inc. and further ordered the company’s CEO, Dr Eitan Konstantino to disgorge the benefits he had received arising from the alleged breach of fiduciary duty, including amounts he had received for assigning his intellectual property rights to Chocolate PTA balloon catheter, royalties on past and future sales of Chocolate PTA, and all of his shares and options in the company.

QT Vascular and its CEO have been advised by their US counsel that they have multiple grounds for appeal, and that the decision of the single judge in a federal district court in Northern California "contains numerous legal errors".

Among others, the defendants and their US counsel believed the trial court may have erred in finding Konstantino, as a director who did not have an invention assignment agreement with AngioScore on whose board he sat, had an obligation to offer his invention to AngioScore, when it had been independently conceived and developed without utilising any resources of AngioScore.

AngioScore, an angioplasty company, initiated patent infringement proceedings on June 29, 2012, against the company's subsidiaries, TriReme Medical, LLC and Quattro Vascular and Konstantino relating to the Chocolate PTA.

On June 27, 2014, AngioScore added claims alleging that Konstantino breached his fiduciary duties to AngioScore by developing the Chocolate PTA and that TriReme US, Quattro Vascular and that QT Vascular aided and abetted the alleged breach.

QT Vascular said the trial court decision “does not have any adverse impact on the defendants' defenses” related to the patent claim which is scheduled for trial in September 2015 and “will not have” a material effect on the financial position or profitability of the company.

Subsequent to the trial court decision, QT Vascular says it has mutually agreed to terminate an agreement with investors ICH Gemini Asia Growth Fund, Toe Teow Heng, Toe Teow Teck and Kuah Ann Thia to subscribe for US$12 million 8% convertible bonds due in 2017, as announced by the company on July 1, 2015.

Biosensors also make similar stuff. Does any one know what are the differences with QT V?

Yes i know i know, pm me if u still interested to know..

sent from my Galaxy Tab S